---
title: "Polaryx Therapeutics (PLYX.US) — Financial Reports"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PLYX.US/norm.md"
symbol: "PLYX.US"
name: "Polaryx Therapeutics"
parent: "https://longbridge.com/en/quote/PLYX.US.md"
datetime: "2026-05-20T20:18:59.643Z"
locales:
  - [en](https://longbridge.com/en/quote/PLYX.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PLYX.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PLYX.US/norm.md)
---

# Polaryx Therapeutics (PLYX.US) — Financial Reports

## Income Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| EPS | -0.0539 | -0.0319 | -0.0312 | -0.0226 | -0.1139 |
| ROE | -288.56% | -121.22% | -133.83% | -107.52% | - |
| Revenue | - | - | - | - | - |
| Net income | -2.54M | -1.50M | -1.43M | -1.01M | -5.05M |
| Operating income | -1.96M | -911000.00 | -974000.00 | -884000.00 | -5.05M |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Profit quality | - | - | - | - | - |

## Balance Sheet (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| A&L | 3.50M | 5.17M | 5.98M | 3.54M | 4.44M |
| Leverage | 1.41 | 1.13 | 1.13 | 1.09 | 1.04 |
| BVPS | 0.0526 | 0.0964 | 0.1127 | 0.0720 | 0.0944 |
| Turnover | - | - | - | - | - |
| Cash & STI | 3.08M | 5.14M | 5.75M | 3.30M | 4.16M |
| Inv & Rec | - | - | - | - | - |
| LT assets | - | - | - | - | - |
| Net debt | -3.08M | -5.14M | -5.75M | -3.30M | -4.16M |

## Cash Flow Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | -2.06M | -1.49M | -887000.00 | -858000.00 | -709000.00 |
| Investing CF | - | - | - | - | - |
| Financing CF | - | 888000.00 | 3.33M | 0.0000 | 250000.00 |
| Free CF | -1.21M | -378375.00 | -113750.00 | -295500.00 | - |
| OCF coverage | - | - | - | - | - |
| Repaid & issued | - | - | - | - | - |
| CapEx | - | - | - | - | - |